Is Zimmer Biomet Holdings Inc (ZBH) a Bargain After 3.9% Drop? GF Value Says Undervalued
On September 08, 2026, Zimmer Biomet Holdings Inc (ZBH) shares fell 3.9% to a current price of $94.22. This decline comes amid a 52-week price range of $79.12 t
ZBH - Zimmer Biomet Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$103.11
DETAILS
HIGH:
$120.00
LOW:
$93.00
MEDIAN:
$104.00
CONSENSUS:
$103.11
UPSIDE:
8.98%
Stock News
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
25,021 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Jupiter Topco LLC
Jupiter Topco LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE: ZBH) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 25,021 shares of the medical equipment provider's stock, valued at approximately $2,156,000. Other institutional investors and hedge funds have
Zimmer Biomet - Showing Signs Of Life
Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026.
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.
Zimmer Biomet Q2 Earnings Call Highlights
Zimmer Biomet (NYSE: ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constant-currency sales rose 4.6%, while international sales increased 3.1%. Chairman, President and
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zimmer Biomet Q2 Earnings Call Highlights
Zimmer Biomet NYSE: ZBH reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript
ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market
ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.
Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.07 per share a year ago.
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis Second quarter diluted earnings per share were $1.03, an increase of 33.8%; adjusted1 diluted earnings per share were $2.07, consistent with the prior year period Company updates full-year 2026 financial guidance WARSAW, Ind., Aug. 5, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and (SIX: ZBH) today reported financial results for the quarter ended June 30, 2026.
Can These 3 MedTech Stocks Hit Targets This Earnings Season?
Can Zimmer Biomet, Charles River Laboratories and Bio-Techne meet earnings expectations? See the MedTech trends and company-specific drivers in focus.
Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards?
ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.
Price Targets
Zimmer Biomet price target raised to $100 from $83 at Canaccord
$100.00
(was $96.55)
Caitlin Cronin
·
Canaccord Genuity
Zimmer Biomet price target raised to $106 from $92 at Truist
$106.00
(was $96.61)
Truist Financial
Zimmer Biomet price target raised to $104 from $92 at Baird
$104.00
(was $97.32)
Robert W. Baird
Zimmer Biomet price target raised to $120 from $115 at UBS
$120.00
(was $97.06)
Patrick Wood
·
UBS
Zimmer Biomet price target raised to $93 from $91 at Bernstein
$93.00
(was $97.53)
Bernstein
Zimmer Biomet price target raised to $96 from $95 at BMO Capital
$96.00
(was $98.16)
BMO Capital
Zimmer Biomet price target raised to $110 from $101 at RBC Capital
$110.00
(was $98.16)
Kendall Au
·
RBC Capital
Zimmer Biomet upgraded to Buy from Sell at UBS
$115.00
(was $92.07)
Patrick Wood
·
UBS
Zimmer Biomet initiated with a Market Perform at BMO Capital
$95.00
(was $87.56)
BMO Capital
Zimmer Biomet price target lowered to $92 from $98 at Truist
$92.00
(was $80.80)
Truist Financial
Zimmer Biomet price target lowered to $83 from $93 at Canaccord
$83.00
(was $82.80)
Canaccord Genuity
Zimmer Biomet price target lowered to $105 from $110 at Stifel
$105.00
(was $82.80)
Rick Wise
·
Stifel Nicolaus
Zimmer Biomet price target lowered to $92 from $100 at Baird
$92.00
(was $82.80)
Robert W. Baird
Zimmer Biomet price target lowered to $94 from $100 at Barclays
$94.00
(was $82.80)
Matt Miksic
·
Barclays
Zimmer Biomet price target lowered to $100 from $104 at Barclays
$100.00
(was $96.69)
Matt Miksic
·
Barclays
Zimmer Biomet price target raised to $89 from $86 at UBS
$89.00
(was $93.69)
UBS
Zimmer Biomet price target lowered to $86 from $88 at UBS
$86.00
(was $85.27)
UBS
Zimmer Biomet price target raised to $99 from $97 at Bernstein
$99.00
(was $94.08)
Bernstein
Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
$93.00
(was $94.08)
David Roman
·
Goldman Sachs
Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI
$120.00
(was $90.02)
Evercore ISI